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ABSTRACT: * 
Background: Delayed puberty is a common condition and, in the absence of an underlying 
condition, is self-limited in most cases. Though delayed puberty appears to be heritable, no 
specific genetic cause has yet been reported. In contrast, many genetic causes have been found 
for idiopathic hypogonadotropic hypogonadism (IHH), a rare disorder in which defects in GnRH 
secretion or action lead to absent or stalled pubertal development. We hypothesized that there is 
a shared genetic basis for both self-limited delayed puberty and IHH. 
Methods: We used two approaches to determine if there is genetic overlap between self-limited 
delayed puberty and IHH. First, in pedigrees with a proband with IHH known to carry a variant 
in an IHH gene, we performed targeted sequencing to determine whether family members with 
self-limited delayed puberty were more likely than family members with normal pubertal timing 
to share the proband’s variant. Second, in probands with self-limited delayed puberty and no 
family history of IHH, we performed whole-exome sequencing and examined 33,855 ethnically 
matched controls drawn from the Exome Aggregation Consortium for variants in 21 IHH genes. 
Variants were characterized as potentially pathogenic based on rarity, severity of mutation, and 
in silico analyses.  
Results: In pedigrees with an IHH proband, the proband’s potentially pathogenic variant was 
shared by 53% (10/19) of delayed puberty family members vs. 12% (4/33) of unaffected family 
members (P = 0.003). In delayed puberty subjects with no family history of IHH, 14% (8/56) had 
potentially pathogenic variants in IHH genes vs. 5.6% (1,907/33,855) of controls (P = 0.01). 
Such variants were found at a higher frequency in subjects with self-limited delayed puberty 
compared to controls in the specific genes IL17RD, TAC3, and TACR3.  
                                                
*Part of this work is currently in press: Zhu J, Choa RE, Guo M, Plummer L, Buck C, Palmert M, et al. A Shared 
Genetic Basis for Self-Limited Delayed Puberty and Idiopathic Hypogonadotropic Hypogonadism. J Clin 
Endocrinol Metab. Epub ahead of print.  
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Conclusions:  For the first time, we report a specific genetic cause for self-limited delayed 
puberty. These findings suggest that variants in IHH genes can contribute to the pathogenesis of 
self-limited delayed puberty. Thus, at least in some cases, self-limited delayed puberty shares an 
underlying pathophysiology with IHH. In addition, our study presents IL17RD, TAC3, and 
TACR3 as candidate genes for future genetic studies of self-limited delayed puberty and 
highlights both the benefits and limitations of genetic testing.  
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GLOSSARY OF ABBREVIATIONS AND GENE NAMES: 
Note: All human gene names are italicized, and the names of proteins encoded by the 
corresponding gene are provided in the right column.  
 
ALS    Acid-labile subunit 
APOE    Apolipoprotein E 
AVPV/PeN               Anteroventral periventricular nucleus/rostral periventricular 
nucleus 
BCH     Boston Children’s Hospital  
CDGP    Constitutional delay of growth and puberty 
CHD7    Chromodomain helicase DNA-binding protein 7 
DMXL2   Rabconnectin-3 
DUSP6   Dual specificity phosphatase 6 
DYN    Dynorphin A 
ExAC    Exome Aggregation Consortium 
FEZF1    FEZ family zinc finger 1 
FGF8    Fibroblast growth factor 8 
FGF17   Fibroblast growth factor 17 
FGFR1    Fibroblast growth factor receptor 1 
FLRT3    Fibronectin leucine rich transmembrane protein 3 
FSH    Follicle-stimulating hormone 
GH    Growth hormone 
GHSR    Growth hormone secretagogue receptor 
GnRH     Gonadotropin-releasing hormone 
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GNRH1   Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) 
GNRHR   Gonadotropin-releasing hormone receptor 
HESX1   Homeobox gene expressed in ES cells 1 
HS6ST1   Heparan sulfate 6-O-sulfotransferase 1 
IGFALS   Insulin-like growth factor-binding protein, acid-labile subunit 
IGSF1    Immunoglobulin superfamily, member 1 
IHH    Idiopathic hypogonadotropic hypogonadism 
IL17RD   Interleukin 17 receptor D 
KAL1    Anosmin-1 
KCNJ11   Potassium inwardly-rectifying channel, subfamily J, member 11 
KISS1    KiSS-1 metastasis-suppressor 
KISS1R   KISS1 receptor 
KNDy    Kisspeptin/neurokinin B/dynorphin 
LEP    Leptin 
LEPR    Leptin receptor 
LH    Luteinizing hormone 
LIN28B   Protein lin-28 homolog B 
NR0B1 (DAX1) Nuclear receptor subfamily 0, group B, member 1 (Dosage-
sensitive sex reversal, adrenal hypoplasia critical region, on 
chromosome X, gene 1) 
NR5A1 (SF1) Nuclear receptor subfamily 5, group A, member 1 (Steroidogenic 
factor 1) 
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NSMF (NELF) NMDA receptor synaptonuclear signaling and neuronal migration 
factor (Nasal embryonic luteinizing hormone-releasing hormone 
factor) 
NHLBI GO ESP National Heart, Lung, and Blood Institute Grand Opportunity 
Exome Sequencing Project 
NKB Neurokinin B 
MGH REU   Massachusetts General Hospital Reproductive Endocrine Unit 
OTUD4   OUT domain-containing protein 4 
PCSK1   Proprotein convertase, subtilisin/kexin-type 1 
PNPLA6   Patatin-like phospholipase domain-containing protein 6 
POLR3A   Polymerase III, RNA, subunit A 
POLR3B   Polymerase III, RNA, subunit B 
PROK2      Prokineticin 2 
PROKR2   Prokineticin receptor 2 
RB&C    Rainbow Babies and Children’s Hospital 
RNF216   Ring finger protein 216 
SEMA3A Semaphorin-3A 
SOX10 SRY-Box 10 
SPRY4    Sprouty homolog 4 (Drosophila) 
STUB1    STIP1 homologous and U box-containing protein 1 
TAC3    Tachykinin 3 (also called neurokinin B) 
TACR3   Tachykinin receptor 3  
TUBB3   Tubulin, beta-3 
WDR11   WD repeat domain 11 
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1 INTRODUCTION: 
Puberty is a striking period of development that bridges childhood and adulthood. It is 
characterized by rapid growth and development of sexual maturity and fertility. Though puberty 
has intrigued scientists for decades, the factors that initiate puberty and regulate pubertal timing 
remain elusive.1 Human disease models in which pubertal timing is altered offer a unique 
opportunity to identify these still unknown factors.  
 
1.1 Function of the hypothalamic-pituitary-gonadal (HPG) axis in puberty 
 Pubertal development is governed by the hypothalamic-pituitary-gonadal (HPG) axis. At 
the onset of puberty, neurons in the hypothalamus release gonadotropin-releasing hormone 
(GnRH), which in turn binds to its receptors in the anterior pituitary to stimulate the production 
and release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH). In early puberty, LH and FSH pulses first appear during sleep and gradually increase in 
both frequency and amplitude during pubertal development and eventually become detectable 
during daytime.2, 3 The gonadotropins LH and FSH subsequently stimulate the gonads to secrete 
sex steroids, which initiate the development of secondary sexual characteristics. In boys, the first 
physical sign that indicates the onset of puberty is testicular growth to a volume of 4 mL or 
greater. In girls, the first sign is the development of breast tissue or thelarche, which is followed 
by the onset of menstruation or menarche approximately 2 years later.4, 5 Sex steroids and 
increasing growth hormone (GH) levels initiate a period of rapid skeletal growth often referred to 
as the pubertal growth spurt.6 Following puberty, ongoing GnRH secretion is essential for the 
maintenance of secondary sexual characteristics, sexual function, and fertility throughout 
adulthood.   
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1.2 Regulation of the HPG axis 
 A complex network of regulatory pathways governs the awakening of the HPG axis at 
puberty. This network synthesizes various hormonal, psychological, and environmental cues, 
which together determine pubertal onset.1 While the influences on pubertal timing, including 
nutritional status, systemic illness, and psychological stress, are known, the exact molecular 
mechanisms that “kick-start” GnRH secretion are still a mystery.1  
Recent work has identified a novel neuron, the kisspeptin neuron in the hypothalamus, as 
a key regulator of GnRH secretion and, thus, pubertal timing.7 The kisspeptin neuron functions 
upstream of the GnRH neuronal network to release the peptide kisspeptin, which binds to its 
receptor located on GnRH neurons and subsequently stimulates the pulsatile release of GnRH 
that drives the activation of the HPG axis.8, 9 Kisspeptin has since been shown to play key roles 
in both positive and negative feedback of sex steroids on the GnRH neuronal network in rodent 
models with kisspeptin-secreting neurons in different locations mediating different effects.10 
Kisspeptin neurons in the arcuate nucleus (ARC) are involved in negative feedback, and studies 
in rodents show that kisspeptin neurons in the anteroventral periventricular nucleus/rostral 
periventricular nucleus (AVPV/PeN) have a positive feedback role thought to mediate the LH 
surge necessary for ovulation (Figure 1).7  
Further work on the regulation of kisspeptin signaling has revealed two additional 
neurotransmitters that are coexpressed with kisspeptin in the arcuate nucleus within the 
hypothalamus, neurokinin B (NKB) and dynorphin A (DYN). These kisspeptin-secreting 
neurons are known collectively as KNDy neurons, named for their coexpression of 
Kisspeptin/Neurokinin B/Dynorphin. KNDy neurons have been shown to function as a complex 
interconnected network thought to regulate GnRH secretion through both positive (NKB) and 
negative (DYN) modulation of kisspeptin signaling (Figure 1).10 
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1.3 Origin of the GnRH neuronal network 
 Animal studies have shown that GnRH neurons originate predominantly from the 
olfactory placodes,11 ectodermal tissue that ultimately differentiates to form the olfactory 
epithelium.12 Following differentiation, the GnRH neurons leave the olfactory placode and 
migrate to their final destination in the hypothalamus with the guidance of nerve fibers from the 
olfactory neurons. Once they reach the hypothalamus, the GnRH neurons project their axons to 
the median eminence, where they access the hypophyseal portal system that delivers hormones to 
the pituitary.11 Though little is known about what molecules and factors guide GnRH neurons to 
their final destination in the hypothalamus, cues from secreted extracellular molecules, growth 
factors, chemokines, neurotransmitters, and ion channels are all thought to play a role.11   
 
1.4 Clinical features and evaluation of delayed puberty 
Delayed puberty is commonly defined as the lack of sexual maturation at an age greater 
than 2 or more standard deviations above the mean for a given population.13 In conventional 
clinical practice, this leads to evaluation of boys who have not achieved a testicular volume of 4 
mL or greater by 14 years and girls who have not started breast development by 13 years.4, 5, 14-17 
However, a recent downward trend in pubertal timing has been observed in the U.S18-21 and other 
developed countries22-25 with significant variability between racial and ethnic groups, which is 
not yet reflected in the clinical age conventions. Thus, these traditional age cut-offs must be 
interpreted with caution, as they may not accurately represent the normative spectrum of puberty 
timing for current populations. 
Several conditions can present with delayed puberty, and the differential diagnoses can 
be divided into four main categories: 1) hypergonadotropic hypogonadism or primary gonadal 
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insufficiency, 2) functional hypogonadotropic hypogonadism, 3) permanent hypogonadotropic 
hypogonadism, and 4) self-limited delayed puberty.13  
1.4.1 HYPERGONADOTROPIC HYPOGONADISM  
Hypergonadotropic hypogonadism, also known as primary gonadal insufficiency, is 
caused by either a congenital or acquired primary defect of the gonads and accounts for 
approximately 10-20% of all delayed puberty presentations.26 Common etiologies include 
Turner’s syndrome, a genetic syndrome in which monosomy of the X chromosome results in 
ovarian dysfunction, and acquired defects in the gonads secondary to chemotherapy or 
radiation.13 The absence of negative sex-steroid feedback from the gonads in these disorders 
results in elevated levels of the gonadotropins LH and FSH and thus, hypergonadotropic 
hypogonadism.  
1.4.2 FUNCTIONAL HYPOGONADOTROPIC HYPOGONADISM 
Functional hypogonadotropic hypogonadism, a condition in which an underlying disorder 
delays maturation of the HPG axis, is the underlying etiology of delayed puberty in 
approximately 20% of all delayed-puberty cases.26 In girls, this is often referred to as functional 
hypothalamic amenorrhea. This is predominantly a transient condition in which stress from a 
systemic illness (inflammatory bowel disease or anorexia nervosa), environmental stressor 
(excessive exercise), or other endocrinopathy (hypothyroidism) essentially “shuts down” the 
HPG axis. This central suppression results in low gonadotropins levels and thus, delayed 
maturation of the gonads, which is reversible with treatment of the underlying condition.13  
1.4.3 PERMANENT HYPOGONADOTROPIC HYPOGONADISM 
In approximately 13% of cases, hypogonadotropic hypogonadism can be a permanent 
disorder, which can be caused by anatomic defects in the central nervous system such as a tumor, 
congenital syndromes such as hypopituitarism or Prader-Willi syndrome, or inflammatory 
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conditions such as hypophysitis.26 In cases when no underlying etiology for permanent 
hypogondatropic hypogonadism can be identified, a diagnosis of congenital or idiopathic 
hypogonadotropic hypogonadism (IHH) is made. In IHH, defects in the secretion or action of 
GnRH lead to low levels of sex-steroids in the presence of inappropriately low levels of 
gonadotropins. Clinically, individuals with IHH have absent or stalled pubertal development by 
adult age (commonly defined as 18 years). Additional clinical features and the genetic etiology 
of IHH will be further discussed in Section 1.5 Idiopathic hypogonadotropic hypogonadism 
(IHH).  
1.4.4 SELF-LIMITED DELAYED PUBERTY 
The most common cause of delayed puberty in both boys and girls is self-limited delayed 
puberty, in which individuals progress through puberty spontaneously prior to reaching adult age 
(18 years). Over 50% of all delayed-puberty cases are due to self-limited delayed puberty.26 A 
subset of individuals with self-limited delayed puberty also have delayed longitudinal growth 
pattern, an entity known as constitutional delay of growth and puberty (CDGP).26 These 
diagnoses can only be made after all other conditions have been ruled out, and spontaneous 
initiation and progression of puberty occurs after a period of clinical observation.  
1.4.5 DIAGNOSTIC DILEMMAS 
Prior to age 18 years, it can be difficult to clinically distinguish patients with self-limited 
delayed puberty from those with IHH, as both conditions are diagnoses of exclusion. While self-
limited delayed puberty resolves on its own, most cases of IHH require lifelong hormone 
therapy.13, 27 Several laboratory tests have been suggested to differentiate the two disorders. 
Basal gonadotropin levels in the pubertal range can occur prior to the physical signs of puberty, 
and, thus, suggest a diagnosis of self-limited delayed puberty. If basal gonadotropins are low, 
successful stimulation of the HPG axis by GnRH or a GnRH agonist can also suggest a diagnosis 
 
 
14 
of self-limited delayed puberty, as stimulated LH levels in the pubertal range can indicate HPG 
axis activation and imminent pubertal initiation.28 However, the lack of a response to GnRH 
stimulation cannot differentiate between the two disorders, as the HPG axis may not yet be active 
in an individual with self-limited delayed puberty and may be permanently defective in an 
individual with IHH.13 To date, no test is available to definitively distinguish between these two 
patient populations. In the absence of a reliable prognostic test, expectant observation remains a 
standard approach in a child presenting with delayed puberty after underlying conditions are 
ruled out, which can affect psychosocial well-being and delay definitive treatment.13  
Understanding the genetics of self-limited delayed puberty is a critical step to 
determining the factors that regulate pubertal timing, which has the potential to guide the 
development of new and effective diagnostic tools and therapies for delayed puberty and other 
reproductive endocrine disorders.  
 
1.5 Idiopathic hypogonadotropic hypogonadism (IHH) 
1.5.1 CLINICAL FEATURES  
IHH is commonly defined as the lack of sexual maturation by age 18 years, with low sex 
steroids and inappropriately low/normal gonadotropins in the absence of any other identifiable 
causes of hypogonadotropic hypogonadism, such as systemic illness, anatomical defect, or other 
endocrinopathy as discussed in Section 1.4.3. Permanent hypogonadotropic hypogonadism.27 
Congenital IHH has been traditionally classified into two entities based on olfactory phenotype. 
IHH with a normal sense of smell is known as normosmic IHH and with defective or absent 
sense of smell as Kallmann’s syndrome.1 Over 60% of individuals with congenital IHH have 
defective or absent smell.29 The defect in olfaction in Kallmann’s syndrome has been suggested 
to result from defects in the migration of olfactory neurons, which in turn disrupts the migration 
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of GnRH neurons.30 In contrast, normosmic IHH is thought to result from defects in the action or 
secretion of GnRH.31  
The reproductive phenotypic spectrum of IHH is broad, ranging from absent pubertal 
development and undetectable serum gonadotropins to partial pubertal development with 
spermatogenesis in men and spontaneous thelarche in women.32, 33 In the majority of cases, 
individuals with IHH require life-long sex steroid replacement and fertility induction with 
pulsatile GnRH or exogenous gonadotropins.13 Notably, up to 20% of individuals with IHH 
undergo “reversal” of their condition with activation of the hypothalamic-pituitary-gonadal axis 
and normalization of reproductive endocrine function in adulthood.34-42 Though the exact factors 
that mediate reversal are unclear, exposure to sex steroids has been suggested to enhance the late 
activation of the GnRH neuronal network.39   
1.5.2 GENETICS OF IHH 
Over the past 20 years, significant advances have been made in understanding the 
genetics underlying IHH (whether in isolation or in the context of a broader syndrome), with 
over thirty genes now implicated in the development, migration, and secretory function of GnRH 
neurons.1, 43-52 These genes have been broadly classified as neurodevelopmental genes critical to 
the development and migration of GnRH neurons, or neuroendocrine genes critical to the 
regulation of GnRH secretion at the level of the hypothalamus or action at the level of pituitary 
(Figure 2).1  
The majority of genes associated with isolated IHH have been implicated in the 
development and migration of GnRH neurons. Notable examples include FGF8 and FGFR1, 
which encode the ligand fibroblast growth factor 8 and its receptor fibroblast growth factor 
receptor 1. These genes are involved in the FGF signaling pathway, a system that plays critical 
roles in mitogenesis, tissue differentiation, and cell migration and survival.53 Studies in mice 
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show that both FGF8 and FGFR1 play critical roles in development of GnRH neurons.53 The 
first variants in FGFR1 and FGF8 were first described in humans with IHH in 200354 and 
2008,55 respectively. Two additional genes implicated in IHH, KAL1 and HS6ST1, are believed 
to be modulators of FGF signaling.56 Furthermore, recent investigations of a group of genes with 
similar roles in neuronal development, referred to as the “FGF8 synexpression group,” have 
implicated an additional six genes (FGF17, IL17RD, DUSP6, SPRY4, and FLRT3) in the 
pathogenesis of IHH.44  
Several genes have been shown to play a role in the regulation of GnRH secretion or 
action. GNRH1, the gene that encodes the prohormone that is ultimately processed to GnRH, and 
GNRHR, which encodes the receptor for GnRH, were obvious candidates, and variants in both 
have been identified in individuals with IHH.57, 58 Variants in the upstream regulators of GnRH 
secretion, kisspeptin and its receptor, encoded by the genes KISS1 and KISS1R, respectively, 
have also been identified in individuals with IHH.8, 9, 59 Most recently, the neurokinin B pathway, 
which is believed to positively regulate kisspeptin signaling as part of the KNDy neuronal 
system in the arcuate nucleus of the hypothalamus, has been implicated in the pathogenesis of 
IHH.10 Variants in both TAC3 and TACR3, genes that encode neurokinin B and its receptor, 
respectively, have been identified in individuals with IHH.60 Of note, IHH with reversal, a 
subtype of IHH in which individuals spontaneously undergo puberty after adulthood, has 
specifically been associated with rare variants in TAC3 and TACR3.34, 40  
 IHH can also be observed as one feature in a broader syndrome. Examples include 
Gordon Holmes syndrome, a rare neurological disorder characterized by ataxia, dementia, and 
hypogonadism, which has been recently associated with variants in the ubiquitination proteins 
encoded by RNF216 and OTUD4,45 and CHARGE syndrome (an acronym for the multiple 
congenital anomalies associated with the syndrome: coloboma, heart anomalies, choanal atresia, 
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retardation, and genital and ear anomalies), which has been associated with variants in CHD7, a 
transcriptional regulator protein.61 The role that these syndromic genes play in the development 
or function of the GnRH neuronal network and the exact reproductive phenotypes associated 
with variants in these genes are still under investigation (Figure 2).45-52  
The inheritance patterns of IHH are diverse and include X-linked recessive with 
mutations in KAL1,62 autosomal dominant with mutations in FGFR1,63 and autosomal recessive 
with mutations in KISS1R8 and GNRHR.57 Even in genes with established inheritance patterns, 
the transmission of IHH caused by variants in these genes is not always uniform.56 For example, 
a study of IHH individuals with rare variants in GNRHR (shown to predominantly follow an 
autosomal recessive pattern) found that over 40% of familial cases followed an autosomal 
dominant pattern of inheritance.64  In addition, variable expressivity and incomplete penetrance 
have been observed in IHH individuals and their relatives with varying reproductive phenotypes 
associated with variants in FGFR1, GNRHR, and IL17RD.32, 44, 65, 66 More recently, some 
individuals with IHH have been found to have variants in two or more IHH-associated genes, 
suggesting an oligogenic basis for a condition previously thought to be monogenic.67 However, 
the extent to which oligogenic inheritance plays a role in the disorder is still unclear.68  
 
1.6 Self-limited delayed puberty 
1.6.1 CLINICAL FEATURES  
In the absence of underlying medical conditions or anatomic defects, as discussed in 
Section 1.4 Clinical features and evaluation of delayed puberty, delayed puberty is typically self-
limited, with individuals progressing through puberty spontaneously prior to reaching an adult 
age (18 years).1 As partial pubertal development with subsequent stalling has been observed in 
individuals with IHH,32, 33 self-limited delayed puberty can only be definitively diagnosed after a 
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period of clinical observation in which the individual initiates and progresses through puberty at 
a normal rate.13 A subset of individuals with self-limited delayed puberty also experience 
longitudinal growth delay, and are further categorized as having CDGP.26  
1.6.2 UNKNOWN GENETICS OF SELF-LIMITED DELAYED PUBERTY 
 Self-limited delayed puberty appears to be highly heritable, as 50-80% of these patients 
have a family history of delayed puberty.69, 70 Many self-limited delayed puberty pedigrees show 
an autosomal dominant pattern, suggesting that the condition can be caused by the effects of 
single-gene mutations.69, 70  
Given these observations, many candidate genes for self-limited delayed puberty have 
been proposed. Leptin, a satiety hormone regulates adipose-tissue mass through hypothalamic 
signaling, and its receptor have previously been implicated in early-onset obesity and delayed 
puberty.71 However, polymorphisms in LEP and LEPR, the genes that encode leptin and its 
receptor, respectively, have not been found to be associated with isolated self-limited delayed 
puberty.72 Another gene implicated in a broader syndrome with delayed puberty is IGSF1, which 
encodes the immunoglobulin superfamily member 1 glycoprotein that is predominately 
expressed in the pituitary and testes.73 Though variants in IGSF1 have been identified in an X-
linked syndrome of central hypothyroidism, macroorchidism, and delayed puberty, they are not 
believed to underlie isolated self-limited delayed puberty.74 
Genes involved in the growth hormone (GH) signaling pathway have also been explored 
as candidates in self-limited delayed puberty. The acid-labile subunit gene IGFALS, which 
encodes a growth-hormone dependent peptide involved in protecting insulin-like growth factor-1 
from degradation, has been implicated in acid-labile subunit (ALS) deficiency, a disorder 
characterized by mild growth retardation with pubertal delay.75 However, no variants in IGFALS 
were identified in a cohort of individuals with self-limited delayed puberty.76 The GH 
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segretagogue receptor, GHSR, which is stimulated by the gastric hormone ghrelin to secrete GH, 
has been implicated in idiopathic short stature and partial isolated GH deficiency with delayed 
puberty.77 Sequencing in GHSR in a group of 96 individuals with idiopathic short stature, 
including 31 with self-limited delayed puberty, revealed two heterozygous variants with 
decreased in vitro signaling activity in two subjects with self-limited delayed puberty.78 Though 
these variants were not identified in controls, future studies with larger cohorts are needed to 
definitively establish this association.  
Large genome-wide linkage and association studies have also been utilized to identify 
candidate delayed puberty genes and loci associated with variation in normal pubertal timing. In 
2008, a genome-wide linkage study revealed a significant association between self-limited 
delayed puberty and a locus on chromosome 2,79 but subsequent genome-wide association 
studies did not detect such a signal. However, four independent genome-wide association studies 
did identify that variation near or in the gene LIN28B, a human homolog of the gene lin-28 in C. 
elegans, which regulates growth progression, was associated with pubertal timing in humans.80-83 
Two recent meta-analyses confirmed this association and identified over 100 additional loci 
associated with age at menarche.84, 85 Furthermore, two studies have also associated variation 
near or at LIN28B with growth in height in addition to pubertal timing.86, 87 Despite these reports, 
no variants in LIN28B were identified in a cohort of individuals with self-limited delayed 
puberty.88 
Given the phenotypic similarities between IHH and self-limited delayed puberty, genes 
underlying isolated congenital IHH, as discussed in Section 1.5.2 Genetics of IHH, have also 
been popular candidate genes for delayed puberty. Several studies have investigated the role of 
both common and rare variants in IHH genes in individuals with self-limited delayed puberty 
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(discussed in detail in Section 4.1 Previous work);89-93 however, no study to date has 
conclusively associated rare variants in IHH genes with self-limited delayed puberty.   
Despite the many promising candidate genes and genetic loci identified through case-
reports, phenotypic similarities between self-limited delayed puberty and known genetic 
disorders, and genome-wide association and linkage studies in individuals with self-limited 
puberty, the exact causal variants and genes underlying delayed puberty remain unknown.  
 
1.7 Connections between self-limited delayed puberty and IHH 
Several observations suggest that there are common pathophysiologic mechanisms that 
link self-limited delayed puberty and isolated IHH. Individuals with delayed puberty and isolated 
IHH can co-exist in the same pedigree,38, 44, 62, 64, 65, 94 and prior studies have reported that over 
10% of IHH patients have relatives with a history of delayed puberty, compared to 2.5% of the 
general population.95, 96 In addition, one distinction between the phenomenon of “reversal” of 
IHH and self-limited delayed puberty is the timing of pubertal initiation: after the age of 18 years 
in IHH with reversal and before age 18 years in self-limited delayed puberty. The specific 
phenotypic resemblance between self-limited delayed puberty and IHH with reversal suggests 
that variants in TAC3 and TACR3, which has been specifically associated with IHH with 
reversal, may also contribute to the pathogenesis of self-limited delayed puberty, but prior 
investigations have not conclusively demonstrated such a link.92, 93  Despite these initial findings, 
our observations suggest that, at least in some cases, self-limited delayed puberty and isolated 
IHH may share an underlying pathophysiology.  
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In this thesis, we have tested the hypothesis that there is overlap between the genetics of 
self-limited delayed puberty and that of isolated IHH† using two approaches. First, we examined 
pedigrees with an IHH proband known to carry a potentially pathogenic variant in an IHH gene 
to determine whether family members with self-limited delayed puberty were more likely than 
those with normal pubertal timing to share the proband’s variant. We also examined probands 
with delayed puberty (and no family history of IHH) to test whether they were more likely than 
controls to harbor potentially pathogenic variants in IHH genes, with a specific focus on TAC3 
and TACR3 given the association of these genes with IHH with reversal. 
 
2 MATERIALS AND METHODS: 
All studies were approved by the Institutional Review Boards (IRBs) of Massachusetts 
General Hospital (MGH), Boston Children’s Hospital (BCH), and Rainbow Babies and 
Children’s Hospital (RB&C), and written informed consent was obtained from all study 
participants.  
 
2.1 Pedigrees with an IHH proband 
2.1.1 STUDY PARTICIPANTS 
IHH individuals were either patients at MGH or referred by their physicians to MGH to 
participate in genetic studies. IHH was defined as low sex-steroid levels (testosterone ≤ 100 
ng/dL in men; estradiol ≤ 20 pg/mL in women) in the setting of inappropriately normal or low 
                                                
†Given the severe phenotypes associated with variants in syndromic IHH genes and the unlikely possibility that 
individuals with self-limited delayed puberty would harbor variants in these genes without additional phenotypes, 
this thesis focuses on only the isolated IHH genes (Figure 2). 
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gonadotropin levels at age ≥18 years in the absence of other identifiable causes of 
hypogonadotropic hypogonadism.27 
Family members in IHH pedigrees were evaluated by a staff member of the MGH 
Reproductive Endocrine Unit through standardized questionnaires, interviews, and/or review of 
medical records. Self-limited delayed puberty was defined in this cohort as 1) spontaneous 
menarche between the ages of 15 and 18 years for girls, initiation of testicular growth between 
the ages of 14 and 18 years for boys, reported or documented diagnosis of delayed puberty by a 
physician, and/or self-reported continual height growth past age 16 years, 2) no report of 
impaired reproductive endocrine function in adulthood, and 3) absence of identifiable underlying 
causes of delayed puberty. Family members who reported normal pubertal development were 
used as controls. 
2.1.2 GENETIC STUDIES 
Genomic DNA was extracted from peripheral blood samples or saliva of all study 
participants. IHH probands had previously been sequenced for variants in 13 IHH genes: FGF8, 
FGFR1, GNRH1, GNRHR, HS6ST1, KAL1, KISS1, KISS1R, NELF, PROK2, PROKR2, TAC3, 
and TACR3. Sequence variants were characterized as potentially pathogenic variants by the 
following criteria: (i) variants with minor allele frequency < 0.1% the 1000 Genomes Project97 
and National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project 
(NHLBI GO ESP);98 (ii) nonsense, frameshift, or splice-site altering variants, and 
nonsynonymous missense variants predicted to be deleterious in ≥ 3/5 in silico prediction 
programs (PANTHER,99 PolyPhen2,100 SIFT,101 pMUT,102 and MutationTaster103). Whenever 
available, previous functional studies of these variants demonstrating loss of function in vitro 
provided additional evidence of pathogenicity. For each IHH proband with an identified 
potentially pathogenic variant, family members for whom DNA was available were screened for 
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the same variant in FGFR1, HS6ST1, KAL1, PROKR2, TAC3, and TACR3 by PCR amplification 
and Sanger sequencing as previously described.38, 40, 41, 62, 94  
 
2.2 Delayed Puberty Probands 
2.2.1 STUDY PARTICIPANTS 
 Delayed puberty participants in the study were either patients at MGH, BCH, or RB&C, 
or referred to MGH to participate in genetic studies. Some of the delayed puberty subjects from 
BCH and RB&C were studied in previous reports on the diagnoses and characteristics of 
adolescents with delayed puberty,26 familial aggregation and inheritance patterns in self-limited 
delayed puberty pedigrees,69 and the role of sequence variation in IHH genes in pubertal 
timing.89, 91 Self-limited delayed puberty was defined in this cohort as 1) absence of spontaneous 
thelarche by age 13 years and spontaneous menarche by age 15 years for girls and testicular 
length <2.5 cm or volume <4 mL at age 14 years or older for boys, 2) spontaneous pubertal 
development prior to age 18 years as evidenced by thelarche and/or spontaneous menarche in 
girls and testicular length ≥ 2.5 cm or testicular volume ≥ 4 mL in volume in boys, and 3) 
evidence of a normal rate of pubertal progression and/or achievement of normal or near-normal 
adult sex-steroid levels and/or testicular volume in boys, and 4) absence of identifiable 
underlying causes of delayed puberty. Controls were 33,855 non-Finnish European individuals 
from the Exome Aggregation Consortium (ExAC).104    
2.2.2 GENETIC STUDIES 
Genomic DNA was extracted from peripheral blood samples or saliva of all study 
participants. Control data were accessioned through the Exome Aggregation Consortium 
browser. Whole-exome sequencing, variant calling, and annotation were performed as described 
below. Variants were filtered using the following parameters: 1) present in one of the following 
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IHH genes: DUSP6, FEZF1, FGF8, FGF17, FGFR1, FLRT3, GNRH1, GNRHR, HS6ST1, 
IL17RD, KAL1, KISS1, KISS1R, NELF, PROK2, PROKR2, SEMA3A, SPRY4, TAC3, TACR3, 
and WDR11; 2) quality designation of PASS; 3) variant frequency within the delayed puberty or 
control cohort of ˂ 20% (to exclude sequencing artifacts); and 4) a potentially pathogenic variant 
as defined above.  
Whole-exome sequencing:  
Library construction was performed as previously described with the following 
modifications: initial genomic DNA input into shearing was reduced from 3µg to 10-100ng in 
50µL of solution.105 For adapter ligation, Illumina paired end adapters were replaced with 
palindromic forked adapters, purchased from Integrated DNA Technologies, with unique 8 base 
molecular barcode sequences included in the adapter sequence to facilitate downstream pooling. 
With the exception of the palindromic forked adapters, the reagents used for end repair, A-base 
addition, adapter ligation, and library enrichment PCR were purchased from KAPA Biosciences 
in 96-reaction kits. In addition, during the post-enrichment SPRI cleanup, elution volume was 
reduced to 20µL to maximize library concentration, and a vortexing step was added to maximize 
the amount of template eluted.  
After library construction, hybridization and capture were performed using the relevant 
components of Illumina's Rapid Capture Exome Kit and following the manufacturer’s suggested 
protocol, with the following exceptions: first, all libraries within a library construction plate were 
pooled prior to hybridization. Second, the Midi plate from Illumina’s Rapid Capture Exome Kit 
was replaced with a skirted PCR plate to facilitate automation. All hybridization and capture 
steps were automated on the Agilent Bravo liquid handling system.   
After post-capture enrichment, library pools were quantified using quantitative PCR 
(automated assay on the Agilent Bravo), using a kit purchased from KAPA Biosystems with 
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probes specific to the ends of the adapters. Based on qPCR quantification, libraries were 
normalized to 2 nM, then denatured using 0.1 N NaOH on the Perkin-Elmer MiniJanus. After 
denaturation, libraries were diluted to 20 pM using hybridization buffer purchased from Illumina.  
Cluster amplification of denatured templates was performed according to the 
manufacturer’s protocol (Illumina) using HiSeq v3 cluster chemistry and HiSeq 2000 or 2500 
flowcells. Flowcells were sequenced on HiSeq 2000 or 2500 using v3 Sequencing-by-Synthesis 
chemistry, then analyzed using RTA v.1.12.4.2 or later. Each pool of whole exome libraries was 
run on paired 76 bp runs, and an 8 base index sequencing read was performed to read molecular 
indices, across the number of lanes needed to meet coverage for all libraries in the pool. 
Exome sequence data processing was performed using the Genome Analysis Toolkit 
(GATK).106 Single-nucleotide polymorphism and insertion/deletion discovery and genotyping 
was performed using standard filtering parameters or variant quality score recalibration 
according to GATK Best Practices recommendations.107, 108  
Annotation of variants was performed with SnpEff version 2.0.5.109 
 
2.3 Statistical analysis:  
For analysis of pedigrees with an IHH proband, the expected percentage of family 
members sharing an IHH proband’s variant under the null hypothesis that the variant has no 
effect on pubertal phenotype was calculated according to the following formula: [(75% * number 
of 1st degree relatives in pedigrees in which the IHH proband had 2 variants) + (50% * number of 
1st degree relatives in pedigrees in which the IHH proband had 1 variant) + (25% * number of 2nd 
degree relatives) + (12.5% * number of 3rd degree relatives)] / [total number of family members]. 
The probability of observing the observed results was determined by performing 106 random 
computer simulations under the null hypothesis and tallying the number of simulations that 
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produced results with a deviation from expected that was equal to or greater than that of the 
observed results (examining the proportion of family members with delayed puberty who shared 
the proband’s variant, the proportion of unaffected family members, or the difference between 
these two proportions).  
For analysis of delayed puberty probands, frequencies of potentially pathogenic variants 
between cases and controls were compared using Fisher's exact test. Comparisons of ages at 
pubertal milestones were performed using Student’s t-test. All tests were two-sided, and a P-
value < 0.05 was considered statistically significant. 
 
3 RESULTS: 
We analyzed two cohorts of subjects with self-limited delayed puberty: family members 
of an IHH proband who themselves had delayed puberty, and individuals with delayed puberty 
and no family history of IHH.  
 
3.1 Pedigrees with an IHH Proband 
3.1.1 ASCERTAINMENT OF PEDIGREES 
Figure 3 summarizes the process of identifying pedigrees with an IHH proband with a 
potentially pathogenic variant in an IHH gene and family members with delayed puberty. Of 
1,354 IHH probands in the Massachusetts General Hospital Reproductive Endocrine Unit (MGH 
REU) research database, 148 had pedigrees with one or more family members noted to have 
delayed puberty. In 131 of these pedigrees, the proband with IHH had previously been screened 
for exonic sequence variants in one or more of thirteen IHH genes, and 59 were found to have 
such a sequence variant with an initial rarity cutoff of a < 1% minor allele frequency in both the 
1000 Genomes Project and the NHLBI GO ESP (See Materials and Methods). DNA was 
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available for family members with delayed puberty in 39 of these pedigrees, and review of 
records revealed that in 23 of these pedigrees the family members recorded as having delayed 
puberty met the criteria for self-limited delayed puberty used for this study (Figure 3). Sequence 
variants identified in the IHH probands were classified as “potentially pathogenic variants” based 
on their rarity (with a more stringent cutoff of a 0.1% minor allele frequency) and predicted 
pathogenicity in 18 of those 23 pedigrees (see Materials and Methods).  
In pedigrees in which the IHH proband had a candidate variant in KAL1, an X-linked 
gene, only female family members were included in the analysis because pathogenic variants in 
KAL1 are highly penetrant for IHH in men;62 this led to removal of one pedigree in which DNA 
was available only for male family members, as any males with a pathogenic variant was highly 
likely to have an IHH phenotype. Two additional pedigrees in which the IHH probands had 
biallelic variants in GNRHR and DNA was available for only the proband’s parents were 
removed, as both parents were assumed to carry one such variant. Of the 15 pedigrees that met 
criteria for inclusion in this analysis, one had an IHH proband with two potentially pathogenic 
variants (in TAC3 and HS6ST1) (Figure 4); all other probands had a single potentially pathogenic 
variant in an IHH gene (Table 1).  
Within these 15 pedigrees, DNA was available from 19 family members with self-limited 
delayed puberty and 33 family members with normal pubertal timing. No single pedigree 
contributed disproportionately: 11 pedigrees contributed one family member with delayed 
puberty each; and the remaining 4 each contributed two family members with delayed puberty. 
All pedigrees contributed 0-3 unaffected family members, except for one pedigree that 
contributed 6 (Table 1). To rule out differences in genetic relatedness as a potential confounding 
factor, the degree of relation of delayed puberty and unaffected family members to the IHH 
proband was assessed across the pedigrees. Of the delayed puberty and unaffected family 
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members, 74% and 79% were first-degree relatives, 21% and 18% were second-degree relatives, 
and 5% and 3% were third-degree relatives, respectively (Figure 3). Based on these degrees of 
relatedness, under the null hypothesis that the proband’s variant has no effect on pubertal 
phenotypes in family members, ~44% of delayed puberty family members and ~44% of 
unaffected family members would be expected to share the IHH proband’s variant. 
3.1.2 GENETIC VARIANTS 
Targeted sequencing was performed to determine whether delayed puberty family 
members and unaffected family members harbored the same variant as the IHH proband. The 
potentially pathogenic variants found in the IHH probands were shared by 53% (10/19) of 
delayed puberty family members compared to 12% (4/33) of unaffected family members (P = 
0.003, determined by 106 random computer simulations under the null hypothesis as described 
above). This difference was primarily due to fewer unaffected family members sharing the IHH 
proband’s variant than expected if the variant had no effect on pubertal timing (12% observed vs. 
44% expected, P < 0.0001). There was also a suggestion of more delayed puberty family 
members sharing the IHH proband’s variant than expected (53% observed vs. 44% expected), 
though this difference was not statistically significant (P = 0.3).  
The genetic variants found to be shared between IHH probands and family members with 
delayed puberty were found in FGFR1 (7 subjects from 6 pedigrees), KAL1 (2 female subjects 
from 1 pedigree), and TAC3 (1 subject). Of the 10 variants identified, 6 led to premature 
termination (FGFR1 p.Q680X, p.R622X x2, and p.S346fsX18; KAL1 p.R457X x2), 1 was a 
missense change previously shown to be loss-of-function in vitro (FGFR1 p.Y99C),65 and 3 were 
missense variants predicted to be pathogenic by 3 or more of 5 in silico prediction programs 
(FGFR1 p.E274G and p.I639T; TAC3 p.R80S) (Table 1).  
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In 2 of these pedigrees, the IHH proband’s variant was also found in family members 
with normal pubertal timing (FGFR1 p.Y99C; KAL1 p.R457X) (Figure 4). In addition, in 2 
pedigrees, the IHH proband’s variant was shared only with unaffected family members. One of 
these two variants led to premature termination (TACR3 p.W208X), and the other was previously 
shown to be loss-of-function in vitro (PROKR2 p.S188L) (Table 1).94  
3.1.3 PHENOTYPES 
Of the 19 delayed puberty family members, 8 were women and 11 were men (Table 2). 
For the women, the average age of menarche (by self-report) was 15.9 years with a range of 15-
17.5 years. For the men, the age of initiation of testicular growth (also by self-report) was 
available for 6 subjects, with an average of 15.3 years and a range of 14-16 years. There were no 
apparent differences in clinical characteristics (e.g., age of menarche, age of testicular growth) 
between the 10 delayed puberty family members with a potentially pathogenic variant in an IHH 
gene and the 9 without such a variant (Table 2). 
 
3.2 Delayed Puberty Probands 
Because IHH is a rare disease, the association of potentially pathogenic variants in IHH 
genes with delayed puberty in relatives of IHH probands could be unique to these special cases. 
To determine whether variants in IHH genes contribute to self-limited delayed puberty outside 
the context of pedigrees with an IHH proband, we used whole-exome sequencing to screen for 
sequence variants in 21 IHH genes in 56 subjects with delayed puberty, no family history of 
IHH, and self-reported European ancestry; 21 were referred to the MGH REU for clinical care 
and/or research studies, and 35 were patients at BCH and RB&C.  We compared the frequency 
of potentially pathogenic variants in delayed puberty subjects to that of 33,855 non-Finnish 
European controls from ExAC.104 Because individual level data was not available in ExAC, each 
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allele with a potentially pathogenic variant was counted as a single individual with such a 
variant.  
3.2.1 GENETIC VARIANTS 
Potentially pathogenic variants in IHH genes were identified in 14.3% (8/56) of delayed 
puberty probands compared to 5.6% (1,907/33,855) of controls (P = 0.01) (Table 3). 
Heterozygous variants identified in delayed puberty probands were found in GNRHR (n = 1, 
1.8% of all delayed puberty subjects), IL17RD (n = 3, 5.4%), SEMA3A (n = 1, 1.8%), TAC3 (n = 
2, 3.6%), and TACR3 (n = 1, 1.8%) (Tables 3 and 4). One potentially pathogenic variant 
identified in delayed puberty subjects led to premature termination (IL17RD p.W200X), one led 
to a splice-site change (TAC3 g.18595G>T, in the donor splice site of exon 9), one was a 
missense variant previously shown to cause loss of function in vitro (IL17RD p.K131T),44 and 
five were missense variants predicted to be deleterious in 3 or more of 5 in silico prediction 
programs (GNRHR p.L117R; IL17RD p.P191L; TAC3 p.H83R; TACR3 p.A171P; SEMA3A 
p.T717I) (Table 4). The GNRHR p.L117R, IL17RD p.K131T, and SEMA3A p.T717I variants 
identified in delayed puberty probands had been previously identified in subjects with IHH at the 
MGH REU and/or reported in prior studies (Table 4),44, 110 as had 49 variants identified in 552 
ExAC controls (Supplemental Table 1). The frequency of these known IHH variants was higher 
in the delayed puberty cohort compared to controls (5.4% vs. 1.6%, respectively), though this did 
not reach statistical significance (P = 0.06). All potentially pathogenic variants identified in 
ExAC controls are listed in Supplemental Table 1.  
Given the association between IHH with reversal and TAC3 and TACR3,34 we 
specifically tested whether potentially pathogenic variants in these genes were enriched in 
subjects with self-limited delayed puberty compared to controls. Indeed, 5.4% (3/56) of delayed 
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puberty probands were found to harbor such variants in TAC3 or TACR3 compared to 0.3% 
(87/33,855) of controls (P = 0.0005) (Table 3).  
The gene with the largest number of potentially pathogenic variants in delayed puberty 
probands was IL17RD, a modulator of signaling by the fibroblast growth factor receptor, with 
variants found in 3 delayed puberty subjects (5.4%) compared to 0.7% (231/33,855) of control 
subjects (Table 3).  
3.2.2 PHENOTYPES 
For women in the delayed puberty cohort for whom the age of menarche was documented 
(12 of 15 women), the average age of menarche was 16.0 years with a range of 15-18 years. For 
men for whom the age at which testicular size reached the pubertal range (≥ 4 mL in volume or ≥ 
2.5 cm in length) was documented (30 of 41 men), the average age of reaching a pubertal 
testicular size was 15.5 years with a range of 14-17 years (Table 5). There were no apparent 
differences in clinical characteristics (e.g., age of menarche, age of testicular growth) between 
subjects recruited from BCH/RB&C and those from the MGH REU (Table 6). There were also 
no apparent differences in clinical characteristics between subjects with potentially pathogenic 
variants in IHH genes and subjects without such variants (Table 5). Of the 8 subjects with 
delayed puberty who had potentially pathogenic variants in IHH genes, 4 subjects were from the 
BCH/ RB&C cohort (11% of the cohort of 35), and 4 subjects were from the MGH REU cohort 
(19% of the cohort of 21). The slightly higher frequency of potentially pathogenic variants 
observed in the MGH REU cohort was not statistically significant (P = 0.5).  
 
4 DISCUSSION: 
We have found that subjects with self-limited delayed puberty are more likely than 
control subjects to carry potentially pathogenic variants in IHH genes, which are critical to the 
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development and function of the GnRH neuronal network. By implicating these genes in the 
pathogenesis of delayed puberty, our findings confirm the genetic basis of delayed puberty that 
had been suggested by previous studies that demonstrated its highly familial nature.69, 70 
Furthermore, the genetic link between delayed puberty and IHH suggests that the common, self-
limited condition of delayed puberty and the rare, often permanent disorder of IHH share 
underlying pathophysiologic mechanisms.  
 
4.1 Previous work 
Several prior studies, some conducted by members of the MGH REU, have tested the 
hypothesis that either common or rare variants in IHH genes contribute to the pathogenesis of 
delayed puberty. These studies have examined both rare and common variants in GNRH1 and 
GNRHR as well as common haplotypes around these genes,89, 90 common variants in a panel of 
10 IHH genes (FGFR1, GNRH, GNRHR, GPR54, KAL1, KISS1, LEP, LEPR, PROK2, 
and PROKR2),91 variants specifically associated with IHH in KAL1, GNRHR, and FGFR1,91 and 
rare variants in FGFR1, GNRHR, TAC3, and TACR3.92, 93 None of these studies demonstrated a 
statistically significant association between any of these variants and delayed puberty, though in 
one study a heterozygous nonsense variant in GNRHR (p.F309X) segregated with the delayed 
puberty phenotype in a pedigree,92 and in another, a missense variant in TACR3 (p.A449S), 
predicted to be benign on in silico analysis, was identified in a delayed puberty subject but not in 
controls.93 Thus, though these studies have identified occasional rare variants in IHH genes in 
delayed puberty individuals, no study to date has conclusively associated rare variants in IHH 
genes with self-limited delayed puberty. Given the similarities between IHH and self-limited 
delayed puberty, the failure to demonstrate such an association was puzzling. The expansion of 
the IHH gene panel over the years and the use of whole-exome sequencing in this study to screen 
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simultaneously for variants in all genes associated with isolated IHH have now allowed us to 
demonstrate an enrichment of rare variants in IHH genes in subjects with self-limited delayed 
puberty.   
 
4.2 Genetic and phenotypic variability in self-limited delayed puberty and IHH 
Our results also highlight the variability in both the genetic variants and phenotypes 
associated with variants in IHH genes. All potentially pathogenic variants identified in delayed 
puberty subjects were heterozygous. While IHH associated with variants in FGFR1 and FGF8 
have been shown to predominantly follow an autosomal-dominant mode of inheritance,54, 55 
heterozygous variants in the remaining genes associated with IHH would not be necessarily be 
expected to lead to a disease phenotype. However, heterozygous variants in TACR3, GNRHR, 
GNRH1, and PROKR2,40, 58, 64, 94 as well as the secreted ligand PROK2111 have been clearly 
associated with the reproductive endocrine dysfunction of IHH.111, 112 One possibility is that 
these variants act in a dominant manner, as some variants in GNRHR have been shown to 
regulate wild-type receptors in a dominant-negative manner.113 Another possibility is that these 
individuals have another defect in a yet-to-be identified gene critical to the function of the GnRH 
network, as IHH has been suggested to have an oligogenic inheritance pattern in some 
instances.67 A third possibility, which stems from the variability in phenotypes associated these 
variants seen in this study, is variable penetrance and expressivity. In a previous study on 
FGFR1, the same heterozygous variants were associated with IHH, delayed puberty, and normal 
reproductive endocrine function within the same pedigree.32 
Similarly in our study, potentially pathogenic variants in multiple IHH genes were found 
not only in subjects with delayed puberty but also in controls. Because limited phenotypic data 
was available for the ExAC controls, it is possible that some controls harboring variants in IHH 
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genes in fact had delayed puberty. Furthermore, though these variants were predicted to be 
deleterious by multiple computer prediction programs, it remains possible that some of these 
variants have little to no impact on the function of the encoded proteins. As discussed above, 
these variants in IHH genes may also exhibit variable penetrance and expressivity. Indeed, in two 
of the IHH pedigrees analyzed in this study, the same heterozygous variant was found in the IHH 
proband, family members with delayed puberty, and family members with normal pubertal 
timing. However, in our analysis of pedigrees with an IHH proband, few unaffected family 
members shared the proband’s variant, suggesting that these IHH gene variants tend to produce 
either delayed puberty or IHH. The genetic and phenotypic variability associated with variants in 
IHH genes complicates the interpretation of genetic testing for these conditions, and future 
studies are needed to more clearly define the genetic variants and their associated phenotypes to 
determine the clinical utility of genetic testing. 
 
4.3 A critical role for the neurokinin B pathway in pubertal timing 
Our results provide further evidence for the association between rare variants in the 
neurokinin B signaling pathway and delayed emergence of reproductive endocrine function, as 
rare variants in TAC3 and TACR3 have now been identified in individuals with self-limited 
delayed puberty as well as in individuals with IHH with reversal. Interestingly, a common 
genetic variant near TACR3 has been shown to be associated with variation in the normal timing 
of puberty.84, 85 Thus, disruption of the neurokinin B pathway can lead to late-normal pubertal 
timing, frankly delayed puberty, or even more severely delayed sexual maturation that does not 
occur until after the age of 18 years, firmly demonstrating a critical role for the neurokinin B 
pathway in influencing pubertal timing. 
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4.4 An emerging role for IL17RD in delayed puberty 
We also identified several potential pathogenic variants in IL17RD, a modulator of the 
FGF8/FGFR1 signaling pathway, which has been suggested to have a role in the fate 
specification of GnRH neurons.44 A recent study identified a heterozygous variant in IL17RD (p. 
S468L) in both an IHH proband and a parent with delayed puberty and another variant in 
IL17RD (p. P577Q) in the homozygous state in an IHH proband and in the heterozygous state in 
one parent who had delayed puberty.44 These findings and our current observations collectively 
suggest that heterozygous variants in IL17RD may produce a partial functional defect resulting in 
reproductive endocrine phenotypes of varying severity. 
 
4.5 Refining the physiological model of puberty 
IHH genes have been broadly classified based on their roles in either the 
neurodevelopmental ontogeny or neuroendocrine physiology of GnRH neurons.1 It is fairly 
plausible that TAC3 and TACR3, neuroendocrine genes that appear to regulate GnRH neuronal 
function, could function as part of the hypothetical “switch” that activates the GnRH neuronal 
network to initiate puberty. Defects in either TAC3 or its receptor TACR3 could disrupt the 
autoregulatory positive feedback loop in KNDy neurons that modulates kisspeptin signaling. 
Abnormal or dampened kisspeptin secretion could in turn disrupt the pulsatile GnRH secretion 
critical to the activation of HPG axis at puberty. It is less clear, perhaps, how delayed puberty 
could be caused by deleterious variants in IL17RD, a presumed neurodevelopmental gene 
involved in the initial fate specification of GnRH neurons.44 One potential mechanism is that 
IL17RD may function not only in the development of GnRH neurons but also in other yet-to-be 
identified pathways critical for activating GnRH neurons at puberty. Another possibility is that 
IL17RD has some positive feedback role, whether direct or indirect, in the known pathways that 
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initiate puberty similar to neurokinin B, which remain poorly understood. A third possibility 
stems from the fact that the hormonal changes underlying puberty can be detected well before 
the appearance of physical signs of puberty: in boys, nighttime LH secretion has been shown to 
occur 1-2 years before testicular enlargement can be appreciated.3 Thus, even if the first 
activation of GnRH neurons occurs at a normal time, impaired activity of the GnRH neuronal 
network due to deleterious variants in a neurodevelopmental gene could result in a longer delay 
between the activation of this diminished GnRH neuronal network and the appearance of the 
physical changes that are used clinically to mark the start of puberty.  
 
4.6 Growth delay in self-limited delayed puberty 
Self-limited delayed puberty has traditionally been described as occurring in the context 
of CDGP, with associated delays in childhood growth and skeletal maturation. However, in one 
study, over 50% of individuals with delayed puberty did not exhibit slow prepubertal growth.114 
This observation suggests two distinct pathophysiological mechanisms for delayed puberty, one 
associated with delays in prepubertal growth and the second with isolated pubertal delay. As the 
GnRH neuronal network is relatively quiescent during childhood, defects in this network would 
not be expected to cause prepubertal growth delay, but rather pubertal delay in the context of a 
normal childhood growth pattern. Longitudinal growth data were not available for most of our 
delayed puberty subjects, and future work will determine whether delayed puberty associated 
with IHH gene variants indeed occurs in the absence of delayed prepubertal growth.  
 
4.7 Strengths and limitations 
Strengths of our study include the use of exome sequencing to analyze the largest IHH 
gene panel (21 genes) in a delayed puberty cohort to date, as well as the use of a large, ethnically 
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matched control cohort.  Limitations of our study include the relatively small size of the cohorts, 
which were mostly underpowered to implicate specific genes in the pathogenesis of self-limited 
delayed puberty, though we have identified candidate genes (TACR3, TAC3, and IL17RD) for 
future genetic studies of delayed puberty. Another limitation is the difference in whole-exome 
capture techniques used for the delayed puberty cohort and the ExAC controls, which could 
potentially result in differences in variant detection. However, all potentially pathogenic variants 
detected in the delayed puberty cases were in genomic regions with adequate coverage in ExAC. 
In addition, because individual level genotype data was not available for the ExAC cohort, each 
allele with a potentially pathogenic variant was counted as a single individual with such a 
variant. As it is possible that a single individual may have had more than one potentially 
pathogenic variant in an IHH gene, we are likely to have overestimated the actual number of 
individuals with potentially pathogenic variants. However, this would have reduced our power to 
detect differences and, thus, does not invalidate our positive findings. A fourth limitation is 
selection bias. Because the MGH REU is a referral center for IHH, the referred delayed puberty 
cases may have been more severe and, thus, not representative of delayed puberty more 
generally. However, no significant differences were found in clinical characteristics or the 
frequency of potentially pathogenic variants between the MGH and BCH/RB&C cohorts. Future 
studies are needed to determine the degree to which variants in IHH genes contribute to delayed 
puberty in more general populations.  
 
4.8 Linking the genetics of rare and common disorders 
Our findings provide evidence for a genetic link between IHH, a rare disease, and self-
limited delayed puberty, a common disorder. Mendelian diseases or syndromes have been 
traditionally attributed to rare variants with large effects on phenotype. In contrast, more 
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common variations in phenotype in the general population with high heritability, such as height, 
are thought to be due to common variants with small but additive effects.115 However, the genes 
underlying the severe, rare diseases have provided insight into the genetics of more common 
heritable phenotypes. Genetic links between rare and common disease entities or clinical traits 
have been previously demonstrated between syndromes with short stature or somatic overgrowth 
and height variation in the general population (HMGA2)116-118 (GDF5),115, 119 neonatal diabetes 
and type 2 diabetes (KCNJ11),120-122 and familial dysbetalipoproteinemia and elevated fasting 
blood lipids (APOE).123, 124 In reproductive endocrinology, a genetic link has been suggested 
between IHH and hypothalamic amenorrhea, a type of reproductive endocrine dysfunction that 
occurs in the setting of excessive exercise, nutritional deprivation, psychological distress, or 
other stressor.125 Our study serves as an additional example of how rare variants with moderate 
to large effects in genes that underlie a rare genetic disease can also contribute to the genetics of 
a more common counterpart. 
 
5 SUMMARY:  
 Puberty remains an intriguing scientific mystery, and the factors that initiate puberty and 
modulate its progression are still largely unknown. Self-limited delayed puberty has been shown 
to be highly heritable, and many candidate genes and genetic loci for the condition have been 
previously proposed. Despite numerous investigations of these genetic candidates, no specific 
variant or gene has been definitively associated with delayed puberty to date.  
In contrast, multiple genes have been implicated in the rare, severe condition of 
idiopathic hypogonadotropic hypogonadism (IHH). Several observations have suggested a link 
between self-limited delayed puberty and IHH.  Individuals with self-limited delayed puberty 
frequently exist in IHH pedigrees, and individuals with a subtype of IHH (IHH with reversal) 
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undergo spontaneous puberty in adulthood. Given these similarities between IHH and self-
limited delayed puberty, we hypothesized that variants in IHH genes also contribute to the 
pathogenesis of self-limited delayed puberty.   
To test our hypothesis, we analyzed the DNA sequences of two cohorts of subjects with 
self-limited delayed puberty: 1) family members of an IHH proband who themselves had delayed 
puberty, and 2) individuals with delayed puberty and no family history of IHH. In both analyses, 
we found that individuals with delayed puberty were significantly more likely to carry a 
potentially pathogenic variant in an IHH gene compared to controls.   
For the first time, we have associated specific genes with self-limited delayed puberty. 
Our results highlight self-limited delayed puberty as an additional human disease model to 
decipher the intricacies of pubertal timing. Specifically, our study identifies TAC3, TACR3, and 
IL17RD as candidate delayed puberty genes. Future genetic studies may firmly establish these 
and other genes in the pathogenesis of delayed puberty, and functional studies will determine 
how these genes regulate pubertal timing.  
More broadly, a better understanding of the genetics underlying diseases with 
abnormalities in pubertal timing may enable critical advances to determining the answer to the 
mystery of “What starts puberty?” Identifying and characterizing the genetic players in self-
limited delayed puberty and IHH has the potential to create new opportunities to discover new 
and effective diagnostic and therapeutic tools for these and other reproductive endocrine 
disorders.  
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8 TABLES AND FIGURES: 
 
Table 1. Potentially Pathogenic Variants in IHH Probands and Family Members 
 
IHH Proband 
Unaffected 
Family Members  
Delayed Puberty 
Family Members            
Pedigree 
Potentially Pathogenic 
Variant 
N with a 
Potentially 
Pathogenic  
Variant/Total 
N with a 
Potentially 
Pathogenic  
Variant/Total Ref. 
1 FGFR1 p.Y99C 1/3 1/1 65†54 
2 FGFR1 p.P366L 0/3 0/1 126 
3 FGFR1 p.Q680X 0/1 1/1 63, 65 
4 FGFR1 p.G237S 0/3 0/2 63† 
5 FGFR1 p.E274G 0/3 1/1 32 
6 FGFR1 p.W737R 0/2 0/1 — 
7 FGFR1 p.R622X 0/1 2/2 32, 54, 127 
8 FGFR1 p.G687R 0/6 0/1 — 
9 FGFR1 p.I639T 0/2 1/2 — 
10 FGFR1 p.S346YfsX18 0/1 1/1 — 
11* HS6ST p.R382W 
TAC3 p.R80S 
0/0 1/1 — 
12 KAL1 p.R457X 1/2 2/2 62 
13 PROKR2 p.S188L 1/2 0/1 94† 
14 PROKR2 p.R85C 0/1 0/1 94 
15 TACR3 p.W208X 1/3 0/1 40 
TOTAL  4/33 (12%)‡ 10/19 (53%)‡  
Abbreviation: —, none identified 
 * Only the TAC3 p.R80S variant was shared by family members. 
† Loss-of-function as indicated by significantly decreased performance in in vitro functional 
assays compared to wild-type 
‡ P = 0.003 in the comparison of the number of unaffected vs. delayed puberty family members 
found to share the IHH proband’s variant. 
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Table 2. Characteristics of Delayed Puberty Subjects in IHH Pedigrees 
 
All Delayed Puberty Subjects 
(N=19) 
Delayed Puberty Subjects with 
Potentially Pathogenic Variants in 
IHH Genes (N=10) 
Men (N=11) Women (N=8) Men (N=6) Women (N=4) 
  
Number or 
Mean 
(range) N 
Number or 
Mean (range) N 
Number or 
Mean (range) N 
Number or 
Mean 
(range) N 
Age at pubertal     
testicular size* (y) 15.3 (14-16) 6 —   15.4 (14-16) 3 — 
 Age at growth spurt (y) 16.2 (14-18) 6 
 
  17.5 (17-18) 2 
  Age at thelarche (y) — 
 
15.3 (15-16) 3 — 
 
15 1 
Age at menarche (y) — 
 
15.9 (15-17.5) 8 — 
 
15.8 (15-16) 4 
Spontaneous fertility 
(number of subjects) 6 † 6 † 4 † 2 † 
Abbreviation: —, not applicable 
* Testicular volume ≥ 4 ml or testicular length ≥ 2.5 cm 
† Unknown number of subjects who sought fertility 
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Table 3. Potentially Pathogenic Variants by Gene in Delayed Puberty Probands 
Gene 
Number of Delayed 
Puberty Subjects 
(N=56) with a 
Potentially Pathogenic 
Variant  % 
Number of Control 
Subjects (N=33,855) 
with a Potentially 
Pathogenic Variant % P* 
DUSP6 0 0.0% 133 0.4% 1 
FEZF1 0 0.0% 19 0.1% 1 
FGF17 0 0.0% 13 0.0% 1 
FGF8 0 0.0% 33 0.1% 1 
FGFR1 0 0.0% 153 0.5% 1 
FLRT3 0 0.0% 39 0.1% 1 
GNRH1 0 0.0% 33 0.1% 1 
GNRHR 1 1.8% 140 0.4% 0.2 
HS6ST1 0 0.0% 69 0.2% 1 
IL17RD 3 5.4% 231 0.7% 0.006 
KAL1 0 0.0% 145 0.4% 1 
KISS1 0 0.0% 6 0.0% 1 
KISS1R 0 0.0% 51 0.2% 1 
NELF 0 0.0% 89 0.3% 1 
PROK2 0 0.0% 72 0.2% 1 
PROKR2 0 0.0% 146 0.4% 1 
SEMA3A 1 1.8% 257 0.8% 0.3 
SPRY4 0 0.0% 62 0.2% 1 
TAC3 2 3.6% 20 0.1% 0.0006 
TACR3 1 1.8% 67 0.2% 0.1 
WDR11 0 0.0% 129 0.4% 1 
TOTAL 8 14.3% 1907 5.6% 0.01 
TAC3+TACR3 3 5.4% 87 0.3% 0.0005 
* P-values are not corrected for multiple comparisons. 
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Table 4. Potentially Pathogenic Variants in Delayed Puberty Probands  
Potentially 
Pathogenic Variant Evidence for Pathogenicity       
Identified in IHH 
Subject(s) Ref. 
  
Severe Variant or 
LOF Ref. 
In silico Predictions 
(Deleterious 
Predictions/Total 
Predictions)*   
 GNRHR p.L117R 
 
5/5  Yes110 
IL17RD p.K131T LOF44 3/4 Yes44 
IL17RD p.P191L 
 
4/4  No 
IL17RD p.W200X nonsense — No 
SEMA3A p.T717I 
 
3/5 Yes (Unpublished) 
TAC3 p.H83R 
 
5/5 No 
TAC3 g.18595G>T splice-site — No 
TACR3 p.A171P 
 
4/5 No 
Abbreviation: LOF, loss-of-function as indicated by significantly decreased performance 
in in vitro functional assays compared to wild-type; Ref., reference; —, not tested 
* Not all prediction programs gave predictions for all variants. 
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Table 5. Characteristics of Delayed Puberty Probands 
 
All Delayed Puberty Probands (N=56) 
Delayed Puberty Probands with 
Potentially Pathogenic Variants in IHH 
Genes (N=8) 
Men (N=41) Women (N=15) Men (N=7) Women (N=1) 
  Mean (range) N Mean (range) N Mean (range) N Mean (range) N 
Age at pubertal 
testicular size* (y) 15.5 (14-17) 30 —   15.7 (15-16) 4 — 
 Age at thelarche (y) — 
 
14.4 (14-15) 11 — 
 
14 1 
Age at menarche 
(y) — 
 
16 (15-18) 12 — 
 
15 1 
Abbreviation: —, not applicable; Ref., references  
* Testicular volume ≥ 4 ml or testicular length ≥ 2.5 cm 
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Table 6. Sub-Cohort Characteristics of Delayed Puberty Probands 
 
BCH/ RB&C (N=35) MGH REU (N=21) 
Men (N=26) Women (N=9) Men (N=15) Women (N=6) 
  
Mean 
(range) N 
Mean 
(range) N 
Mean 
(range) N 
Mean 
(range) N 
Age at pubertal    
testicular size* (y) 15.3 (14-17) 22 —   15.9 (15-17) 8 — 
 Age at thelarche (y) — 
 
14.3 (14-15) 9 — 
 
14.5 (14-15) 2 
Age at menarche (y) — 
 
15.9 (15-18) 7 — 
 
16.2 (16-17) 5 
Abbreviation: MGH REU, Massachusetts General Hospital Reproductive Endocrine Unit, BCH, 
Boston Children's Hospital; RB&C, Rainbow Babies and Children's Hospital, —, not applicable 
* Testicular volume ≥ 4 ml or testicular length ≥ 2.5 cm 
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Figure 1. Function and regulation of the hypothalamic-pituitary-gonadal axis. Kiss1 neurons in the 
anteroventral periventricular nucleus/rostral periventricular nucleus (AVPV/PeN) and KNDy neurons in the 
arcuate nucleus (ARC) both secrete kisspeptin, which acts on GnRH neurons to secrete pulsatile 
gonadotropin-releasing hormone (GnRH). GnRH binds to receptors on the anterior pituitary to activate 
secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which act 
on the gonads to produce the sex steroids estradiol and testosterone. The sex steroids form negative 
feedback loops with the hypothalamus and pituitary to regulate GnRH and gonadotropin secretion. KNDy 
neurons secrete dynorphin A (DYN) and neurokinin B (NKB) in addition to kisspeptin, which are negative 
and positive autoregulators of kisspeptin signaling, respectively. The Kiss1 neurons in the AVPV/PeN are 
involved in positive feedback regulation by estradiol believed to mediate the gonadotropin surge that 
governs ovulation. Plus sign (+) indicates positive regulation, minus sign (-), negative regulation. Figure 
adapted from Navarro and Tena-Sempere et al. 2012.7 
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Figure 2. Genes implicated in idiopathic hypogonadotropic hypogonadism (IHH). In individuals with 
isolated IHH, variants have been identified in two main categories of genes: 1) Neurodevelopmental 
genes critical to the development and migration of GnRH neurons, and 2) Neuroendocrine genes critical 
to the regulation of GnRH secretion or action. In individuals with IHH in the context of a broader 
syndrome, variants have been identified in a wide variety of genes. The role that these syndromic genes 
play in the pathogenesis of IHH and the reproductive phenotypes associated with variants in these genes 
are still under investigation. Figure adapted from Bianca and Kaiser 2009.56  
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Figure 3. Ascertainment of family members with delayed puberty and normal pubertal timing in pedigrees 
with IHH probands. N, number of individuals specified in associated rectangle.  *Three pedigrees were 
excluded: one in which the IHH proband had a potentially pathogenic variant in KAL1 and DNA was 
available only for male family members, and two in which the IHH probands had biallelic variants in 
GNRHR and DNA was available for only the proband’s parents. † P = 0.003 in the comparison of the 
number of unaffected vs. delayed puberty family members found to share the IHH proband’s variant. 
 
 
59 
 
 
Figure 4. Examples of pedigrees with potentially pathogenic variants that segregate with IHH and delayed 
puberty (Pedigrees 3 and 11 from Table 1) and of a pedigree with a potentially pathogenic variant that 
does not (Pedigree 1). Arrows identify the IHH proband. Genotypes of subjects for whom DNA was 
available are listed below each subject’s symbol. Plus sign (+) indicates the wild-type allele. Squares 
represent males, circles females. 
  
 
 
60 
 
Supplemental Table 1. Potentially Pathogenic Variants in ExAC Controls 
Potentially Pathogenic 
Variant Evidence for Pathogenicity       
Identified in 
IHH  
Subject(s) Ref. 
Number of 
Variant 
Alleles†  
  
Severe 
variant or 
LOF Ref. 
In silico 
predictions 
(deleterious 
predictions/ total 
predictions)*     
DUSP6 p.T381A  4/5  1 
DUSP6 p.L378P  4/4  1 
DUSP6 p.N371H  3/4  3 
DUSP6 p.C353R  4/5  2 
DUSP6 c.1048delA: 
p.S350fs 
frameshift —  1 
DUSP6 p.T346M  4/5 Yes1 25 
DUSP6 p.S331F  5/5  1 
DUSP6 p.S315L  4/5  1 
DUSP6 p.H292R  4/5  1 
DUSP6 p.E281A  3/5  2 
DUSP6 p.A275S  3/5  1 
DUSP6 p.P259T  5/5  1 
DUSP6 p.L246P  4/5  1 
DUSP6 p.Y235H  3/5  1 
DUSP6 p.L214V  4/5  1 
DUSP6 p.D187Y  3/4  1 
DUSP6 p.S182F  4/4  80 
DUSP6 p.R128W  4/4  8 
DUSP6 p.S17R  3/4  1 
FEZF1 p.Q397X nonsense —  1 
FEZF1 
c.1102_1103insT: 
p.H368fs 
frameshift —  1 
FEZF1 p.Y359C  4/5  1 
FEZF1 p.G350S  4/5  1 
FEZF1 p.P343Q  4/5  1 
FEZF1 p.P315T  4/5  1 
FEZF1 p.H272Y  3/5  5 
FEZF1 p.N270T  3/5  1 
FEZF1 g.7057C>T splice-site —  1 
FEZF1 p.C262X nonsense —  1 
FEZF1 p.G251C  3/5  1 
FEZF1 p.P79H  4/5  1 
FEZF1 p.M74V  3/5  1 
FEZF1 p.H66L  3/5  1 
FEZF1 p.R35Q  4/5  1 
FGF17 c.35_35del: 
p.L12fs 
frameshift —  1 
FGF17 p.G25E  3/5  1 
FGF17 p.N27Y  4/5  1 
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FGF17 p.G70R  4/5  2 
FGF17 p.R72C  4/5  2 
FGF17 p.D79Y  4/5  1 
FGF17 p.G80C  4/5  1 
FGF17 p.P120L  4/5  3 
FGF17 p.R210G  5/5  1 
FGF8 p.R222H  3/5  1 
FGF8 p.R222C  5/5  6 
FGF8 p.R219C  5/5  1 
FGF8 p.T218M  3/5  2 
FGF8 p.P215L  5/5  1 
FGF8 p.F209L  3/5  1 
FGF8 p.R208S  4/5  1 
FGF8 p.E204K  4/5  1 
FGF8 p.R198W  5/5  2 
FGF8 p.P197L  4/5  1 
FGF8 p.R188H  3/5  1 
FGF8 p.R188C  5/5  2 
FGF8 p.R176Q  5/5  1 
FGF8 p.R176W  5/5  1 
FGF8 p.R173H  5/5  1 
FGF8 p.R173C  5/5  2 
FGF8 p.N155S  3/5  1 
FGF8 p.G123D  4/5  1 
FGF8 p.R118Q  4/5  1 
FGF8 p.V106L  4/5  1 
FGF8 p.T78I  4/5  1 
FGF8 p.Y72H  4/5  3 
FGFR1 p.R822H  4/4  4 
FGFR1 p.R822C  4/4  10 
FGFR1 p.R821H  4/5  1 
FGFR1 p.R821C  4/4  1 
FGFR1 p.P811R  4/5  3 
FGFR1 p.R809X nonsense —  1 
FGFR1 p.C806X nonsense —  1 
FGFR1 p.C806Y  5/5  1 
FGFR1 p.P800L  3/4 Yes2 6 
FGFR1 p.H798R  5/5  2 
FGFR1 
c.2370_2371del: 
p.S790fs 
frameshift —  1 
FGFR1 p.T787M  5/5  6 
FGFR1 p.R784Q  4/4  4 
FGFR1 p.D782N  3/5  2 
FGFR1 p.V758M  3/5  1 
FGFR1 p.R756H  5/5  2 
FGFR1 p.E728K  5/5  1 
FGFR1 p.E715D  3/5  1 
FGFR1 p.G703S  4/5 Yes3 3 
FGFR1 p.R675P  5/5  3 
FGFR1 p.D652N  5/5  1 
FGFR1 p.N635I  4/4  1 
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FGFR1 p.R609Q  5/5  1 
FGFR1 
c.1818_1819insATCT
TCAC: p.V607fs 
frameshift —  1 
FGFR1 p.P591L  3/4  1 
FGFR1 p.E571K  5/5  1 
FGFR1 p.S565C  5/5  1 
FGFR1 p.I560T  5/5  1 
FGFR1 p.H541D  5/5  1 
FGFR1 p.G539E  5/5  1 
FGFR1 p.M532T  5/5  2 
FGFR1 p.A520T  4/5 Yes4 1 
FGFR1 p.M515T  5/5  1 
FGFR1 p.R507H  3/5  8 
FGFR1 p.P483R  4/5  1 
FGFR1 p.P483S  4/5  1 
FGFR1 p.R475Q  5/5  1 
FGFR1 p.R470C  4/5  2 
FGFR1 p.Y463C  4/5  1 
FGFR1 p.V460F  4/5  1 
FGFR1 p.P455A  3/5  1 
FGFR1 p.R448Q  3/5  1 
FGFR1 p.R448W  5/5 Yes5 1 
FGFR1 p.R445Q  4/5  2 
FGFR1 p.R445W  5/5  1 
FGFR1 p.G440E  3/5  4 
FGFR1 p.S439C  5/5  1 
FGFR1 p.S436C  5/5  3 
FGFR1 p.S434R  4/5  1 
FGFR1 p.R425I  4/4  1 
FGFR1 p.R424H  3/4  4 
FGFR1 p.V358I  3/5  1 
FGFR1 p.Q334X nonsense —  1 
FGFR1 p.G301D  3/4  1 
FGFR1 p.P252R  5/5  1 
FGFR1 p.V248M  4/5  1 
FGFR1 p.D246G  5/5  1 
FGFR1 p.V232L  4/5  1 
FGFR1 p.N227S  3/5  1 
FGFR1 p.R189H  3/5  6 
FGFR1 p.P158L  4/5  1 
FGFR1 g.40490G>C splice-site —  1 
FGFR1 p.T141R  3/4 Yes6 7 
FGFR1 p.S135F  4/4  1 
FGFR1 p.S134F  4/4  1 
FGFR1 p.D130N  4/5  1 
FGFR1 p.D129A  4/5 Yes4 3 
FGFR1 p.T111I  3/5  1 
FGFR1 p.R80H  3/5  2 
FGFR1 p.R80C  3/5  1 
FGFR1 p.R68W  4/5  1 
FGFR1 p.R54C  3/5  2 
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FGFR1 g.28530G>T splice-site —  1 
FGFR1 p.P28L  4/5  4 
FGFR1 p.P23L  4/5  3 
FGFR1 p.R22G  4/5  1 
FGFR1 p.L18F  3/5  1 
FGFR1 p.A16V  3/5  2 
FGFR1 p.L13P  3/5  1 
FGFR1 g.11299A>G splice-site —  1 
FLRT3 p.Y636H  4/5  1 
FLRT3 p.R634Q  4/4  4 
FLRT3 p.L622P  3/4  1 
FLRT3 p.T613I  4/4  1 
FLRT3 p.N584K  4/5  1 
FLRT3 p.Y565C  4/4  2 
FLRT3 p.G534D  5/5  1 
FLRT3 p.I533T  5/5  1 
FLRT3 p.P481L  4/5  1 
FLRT3 p.P471A  3/5  1 
FLRT3 p.G379R  3/5  1 
FLRT3 p.G331E  3/5  1 
FLRT3 p.R317C  4/5  3 
FLRT3 p.R303P  5/5  1 
FLRT3 p.R303H  4/5  2 
FLRT3 p.R275G  3/5  3 
FLRT3 p.R234Q  3/5  1 
FLRT3 p.R203C  4/5  1 
FLRT3 p.L201V  3/5  1 
FLRT3 p.S167G  4/5  1 
FLRT3 p.L159F  4/5  1 
FLRT3 p.I145T  4/5  1 
FLRT3 p.L109F  4/5  1 
FLRT3 p.L109V  4/5  3 
FLRT3 p.L95X nonsense —  1 
FLRT3 p.L90V  4/5  1 
FLRT3 p.I70X nonsense —  1 
FLRT3 p.I56M  3/5  1 
GNRH1 p.K90N  4/5  18 
GNRH1 p.Q89X nonsense —  1 
GNRH1 p.R73X nonsense — Yes7  1 
GNRH1 p.C63Y  5/5  2 
GNRH1 p.I48R  3/5  7 
GNRH1 p.E39K  4/5  2 
GNRH1 p.R36T  5/5  1 
GNRH1 c.60dupC: 
p.C21fs 
frameshift —  1 
GNRHR p.N305Y  4/5  1 
GNRHR p.W291S  3/5  1 
GNRHR p.T269M  4/5 Yes8 2 
GNRHR p.R262W  5/5  1 
GNRHR p.K217X nonsense —  1 
GNRHR p.R240W  5/5  1 
GNRHR p.I235N  4/5  1 
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GNRHR p.N231K  3/5  1 
GNRHR p.N212K  4/5 Yes 
(Unpublished) 
1 
GNRHR p.C200Y LOF9-13 5/5 Yes9 5 
GNRHR p.G188V  3/5  1 
GNRHR p.S187C  4/5  1 
GNRHR p.A171T LOF13, 14 4/5 Yes14, 15 1 
GNRHR p.P146S  4/5  76 
GNRHR p.R139H LOF13, 16 5/5 Yes15, 16 13 
GNRHR p.A129D LOF11, 13, 17 5/5 Yes17 1 
GNRHR p.A127V  3/5  9 
GNRHR p.Y126C  4/5  1 
GNRHR p.P96S  4/5 Yes15, 18 1 
GNRHR p.V94A  4/5  15 
GNRHR p.T91P  4/5  1 
GNRHR p.S74X nonsense —  1 
GNRHR p.W63C  4/4  3 
GNRHR p.F46S  4/5  1 
HS6ST1 p.G396C  3/4  1 
HS6ST1 p.R382W Yes19 4/4 Yes19 34 
HS6ST1 p.R378P  3/4  2 
HS6ST1 p.R378C  3/4  2 
HS6ST1 p.R375C  4/4  1 
HS6ST1 p.R371C  4/4  3 
HS6ST1 p.R367H  3/4  1 
HS6ST1 p.R367C  4/4  1 
HS6ST1 p.D342G  3/4  1 
HS6ST1 p.R336C  4/4  1 
HS6ST1 p.R335W  4/4  4 
HS6ST1 p.V327M  3/4  1 
HS6ST1 p.R323Q  3/4 Yes19 1 
HS6ST1 p.R323W  4/4  1 
HS6ST1 p.T322M  3/4  1 
HS6ST1 p.R314Q  3/4  5 
HS6ST1 p.T307M  4/4  1 
HS6ST1 p.R306W Yes19 4/4 Yes19 2 
HS6ST1 p.R214H  3/4  2 
HS6ST1 p.S207L  3/4  1 
HS6ST1 p.R196Q  3/4  1 
HS6ST1 p.R190C  4/4  1 
HS6ST1 p.G39E  3/3  1 
IL17RD p.A735V  3/4 Yes1 9 
IL17RD p.A722G  3/4  1 
IL17RD p.A722T  3/4  1 
IL17RD p.L715P  4/4  1 
IL17RD p.S712C  4/4  1 
IL17RD p.G701D  3/4  1 
IL17RD p.E673Q  4/5  1 
IL17RD p.S671L  4/4  4 
IL17RD p.S667L  3/4  2 
IL17RD p.Y665C  4/4  2 
IL17RD p.S662X nonsense —  1 
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IL17RD p.P659L  4/4  1 
IL17RD p.H648P  3/4  1 
IL17RD p.G631W  3/4  1 
IL17RD p.Q563X nonsense —  1 
IL17RD p.E561K  4/4  1 
IL17RD p.P557R  4/4  4 
IL17RD p.Q551X nonsense —  1 
IL17RD p.M549R  4/4  8 
IL17RD p.I546T  4/5  2 
IL17RD p.S541F  4/4  2 
IL17RD p.R540W  3/4  10 
IL17RD p.S536R  4/4  2 
IL17RD p.S536G  4/5  4 
IL17RD p.R514X nonsense —  1 
IL17RD p.S513F  4/4  5 
IL17RD p.S513C  4/4  1 
IL17RD p.P505L  4/4  2 
IL17RD p.D493Y  4/4  2 
IL17RD p.P489S  4/4  1 
IL17RD p.Y479X nonsense —  1 
IL17RD p.I457M  4/5  4 
IL17RD p.S444W  3/4  1 
IL17RD p.V421A  4/5  8 
IL17RD p.I419T  4/5  7 
IL17RD p.W407S  4/4  1 
IL17RD p.D392V  4/4  2 
IL17RD p.L381F  4/5  1 
IL17RD p.Y379C  3/4 Yes1 9 
IL17RD p.Y343C  3/4  1 
IL17RD p.R322C  4/4  6 
IL17RD p.T315M  3/4  6 
IL17RD p.A314V  3/4  1 
IL17RD p.P293Q  4/4  1 
IL17RD p.R244X nonsense —  2 
IL17RD p.F242S  4/4  1 
IL17RD p.E239K  4/5  1 
IL17RD p.K235R  4/5  1 
IL17RD p.P222L  4/4  2 
IL17RD g.64198G>A splice-site —  1 
IL17RD p.P191L  4/4  3 
IL17RD g.64151A>G splice-site —  1 
IL17RD p.R183Q  3/4  2 
IL17RD p.E172K  4/5  1 
IL17RD p.P165S  4/4  1 
IL17RD p.V161I  4/5  2 
IL17RD p.T157M  4/4  2 
IL17RD g. 60115G>A splice-site —  1 
IL17RD p.P133L  3/4  5 
IL17RD p.D132E  4/5  5 
IL17RD p.K131T LOF1 3/5 Yes1 58 
IL17RD p.Q126X nonsense —  1 
IL17RD p.S120L  3/4  2 
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IL17RD p.L118P  3/4  1 
IL17RD p.L115P  3/4  1 
IL17RD p.P100L  3/4  1 
IL17RD p.V92G  4/4  4 
IL17RD p.I75M  4/5  4 
IL17RD c.212_213del: 
p.G71fs 
frameshift —  1 
IL17RD c.206dupC: 
p.P69fs 
frameshift —  1 
IL17RD p.Y66C  4/4  2 
IL17RD p.T38I  3/4  1 
KAL1 g.197870T>A splice-site —  3 
KAL1 p.P653L  4/5  8 
KAL1 p.T649M  3/5 Yes5, 6 3 
KAL1 p.P644L  5/5  4 
KAL1 p.G641R  5/5  3 
KAL1 g.196597G>A splice-site —  2 
KAL1 p.L612V  3/5  5 
KAL1 p.Q608L  5/5  4 
KAL1 p.N599K  4/5  6 
KAL1 p.A590V  3/5  1 
KAL1 p.F569L  3/5  1 
KAL1 p.G567S  4/5  6 
KAL1 p.N564S  3/5  2 
KAL1 p.S555C  5/5  3 
KAL1 p.G528W  4/5  3 
KAL1 p.P521S  5/5  2 
KAL1 p.P521T  4/5  1 
KAL1 p.R506W  4/5  1 
KAL1 p.R461W  4/5  2 
KAL1 p.G432R  4/5  2 
KAL1 p.R427C  5/5  4 
KAL1 p.S396L  3/5 Yes20 19 
KAL1 p.R384W  5/5  2 
KAL1 p.T378M  3/5  1 
KAL1 p.Q375R  3/5  1 
KAL1 p.G354W  5/5  1 
KAL1 p.R348W  3/4  2 
KAL1 p.V330A  3/5  2 
KAL1 p.R282H  3/5  1 
KAL1 p.R282C  5/5  2 
KAL1 p.R282S  3/5  3 
KAL1 p.A241T  3/5  1 
KAL1 p.S230R  3/5  2 
KAL1 p.K185N  4/5 Yes5, 21 32 
KAL1 p.H170Q  3/5  5 
KAL1 p.A144P  4/5  2 
KAL1 p.D133N  3/5  3 
KISS1 p.R120S  4/4  1 
KISS1 p.W114C  4/4  1 
KISS1 p.N113K  4/4  1 
KISS1 p.P95R  4/4  1 
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KISS1 p.S77I  3/4 Yes22 1 
KISS1 p.G35S  3/3 Yes22 1 
KISS1R p.Y65C  4/5  1 
KISS1R p.R74G  3/5  3 
KISS1R p.N78S  3/5  1 
KISS1R g.2203G>T splice-site —  1 
KISS1R p.T132I  4/5  13 
KISS1R p.M136R  4/5  1 
KISS1R p.A159E  4/5  1 
KISS1R p.S170C  4/5  1 
KISS1R p.S197I  4/5  4 
KISS1R p.A203D  5/5  1 
KISS1R p.W276C  5/5  1 
KISS1R p.P278S  4/5  1 
KISS1R p.L283P  3/5  1 
KISS1R p.Q286X nonsense —  1 
KISS1R p.Y302H  3/5  5 
KISS1R p.Y313H LOF23 4/5 Yes23 2 
KISS1R p.L321P  5/5  1 
KISS1R p.A324T  3/5  1 
KISS1R p.S328X nonsense —  1 
KISS1R p.R331Q  3/5  1 
KISS1R p.F334L  3/5  1 
KISS1R c.1005delC: 
p.R335fs 
frameshift —  1 
KISS1R p.C389X nonsense — Yes5 7 
NELF p.D528Y  4/4  1 
NELF p.D528N  3/4  2 
NELF p.R518H  4/4  1 
NELF p.R513C  4/4  1 
NELF p.T505M  3/4  1 
NELF g. 9842A>C splice-site —  1 
NELF p.G499R  3/3  1 
NELF p.L495H  4/4  1 
NELF p.Y485C  3/4  1 
NELF p.N477S  3/4  1 
NELF p.R446C  4/4  1 
NELF p.R443W  4/4  1 
NELF p.H439Y  3/4  2 
NELF p.M437V  3/4  1 
NELF g. 9842A>C splice-site —  1 
NELF p.I391T  4/4  1 
NELF p.P370L  4/4  1 
NELF p.R367Q  4/4  1 
NELF p.R367W  4/4  2 
NELF p.R366H  4/4  1 
NELF p.I364V  4/5  1 
NELF 
c.1146_1147insG: 
p.P5fs 
frameshift —  4 
NELF p.G342V  4/4  10 
NELF p.T340I    2 
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NELF p.A335T  3/4  1 
NELF p.L325R  4/4  1 
NELF p.E323K  4/4  2 
NELF p.T317M  4/4  2 
NELF p.S314C  4/4  1 
NELF g.6153A>G splice-site —  1 
NELF p.S305C  4/4  3 
NELF p.R283H  4/4  1 
NELF p.E251Q  4/5  1 
NELF p.R250Q  4/4  3 
NELF p.R250W  4/4  1 
NELF p.R247H  4/4  1 
NELF p.E244D  4/5  1 
NELF p.A243T  4/5  3 
NELF g. 2925G>A splice-site —  1 
NELF p.R215H  4/4  2 
NELF p.R215C  4/4  3 
NELF p.P213L  3/4  7 
NELF p.D211Y  4/4  1 
NELF p.R196C  4/4  1 
NELF p.S193C  3/4  2 
NELF p.R180W  3/4  3 
NELF p.Q172H  4/5  1 
NELF p.R161H  3/3  4 
NELF p.R161C  3/3  2 
PROK2 p.R117W  5/5  1 
PROK2 p.C115Y  5/5  1 
PROK2 p.R101W  5/5 Yes2 9 
PROK2 
c.296dupT:p.F99fs 
frameshift —  8 
PROK2 p.R73H  3/5 Yes5 1 
PROK2 p.R73C  5/5 Yes20, 24 4 
PROK2 p.S67R  4/5  4 
PROK2 p.G62D  5/5  2 
PROK2 p.I55X nonsense — Yes 
(Unpublished) 
13 
PROK2 p.K53N  3/5  1 
PROK2 p.S49N  4/5  1 
PROK2 p.G41D  5/5 Yes25 22 
PROK2 p.Q39R  4/5  5 
PROKR2 p.T335M  3/5  1 
PROKR2 c.990delC: 
p.T330fs 
frameshift —  1 
PROKR2 p.E319K  3/5  2 
PROKR2 p.Y311C  4/5  1 
PROKR2 p.H310Q  3/5  1 
PROKR2 p.D299V  3/5 Yes26 1 
PROKR2 p.G293S  3/5  3 
PROKR2 p.P290S LOF27 4/5 Yes20 9 
PROKR2 p.A289E  5/5  1 
PROKR2 p.W288R  5/5  1 
PROKR2 p.C287G  4/5  1 
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PROKR2 p.T282M  3/5  1 
PROKR2 p.V274D LOF28 4/5 Yes29 1 
PROKR2 p.T273M  3/5  3 
PROKR2 p.R270H  4/5  4 
PROKR2 p.R270C  4/5 Yes21 1 
PROKR2 p.R268H  5/5  18 
PROKR2 p.R264C  4/5  1 
PROKR2 p.T260M LOF28 4/5 Yes21 5 
PROKR2 p.G257E  4/4  9 
PROKR2 p.R248W  3/5  1 
PROKR2 p.G234D  4/5 Yes30 2 
PROKR2 p.V233M  3/5  1 
PROKR2 p.L218P  3/5  2 
PROKR2 p.R164P  4/5  3 
PROKR2 p.K162X nonsense — Yes6 1 
PROKR2 p.A148T  3/5  1 
PROKR2 p.R135H  4/5  1 
PROKR2 p.R135C  4/5  6 
PROKR2 p.R117W  4/5  2 
PROKR2 p.V115M LOF31 4/5 Yes31 1 
PROKR2 p.D112Y  4/5 Yes6 1 
PROKR2 p.D99N  3/5  1 
PROKR2 p.S98Y  4/5  1 
PROKR2 p.A96T  3/5  1 
PROKR2 p.N86D  3/5  1 
PROKR2 p.R85C LOF27, 31, 32 4/5 Yes31  39 
PROKR2 p.R80S  3/5  1 
PROKR2 p.G70S  4/5  3 
PROKR2 p.G68S  4/5  2 
PROKR2 p.G57V  3/5  1 
PROKR2 p.G57C  3/5  1 
PROKR2 c.58delC: 
p.H20fs 
frameshift —  8 
SEMA3A p.R734W  4/5  1 
SEMA3A p.T717I  3/5 Yes 
(Unpublished) 
106 
SEMA3A p.P713A  4/5  1 
SEMA3A p.A651V  5/5  1 
SEMA3A p.A651T  3/5  1 
SEMA3A p.R637H  4/5  4 
SEMA3A p.G633V  5/5  1 
SEMA3A p.E620K  4/5  3 
SEMA3A p.R613X nonsense —  1 
SEMA3A p.A604P  5/5  1 
SEMA3A p.S601L  4/5  1 
SEMA3A p.K600M  5/5  5 
SEMA3A p.E589Q  3/5  2 
SEMA3A p.L564R  4/5  1 
SEMA3A p.R554G  5/5  1 
SEMA3A p.R552C  5/5  2 
SEMA3A p.R544C  4/5  1 
SEMA3A p.R531Q  5/5  1 
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SEMA3A p.R531X nonsense —  1 
SEMA3A p.A530S  3/5  1 
SEMA3A p.L529V  4/5  1 
SEMA3A p.R516Q  3/5  2 
SEMA3A p.R516W  5/5  6 
SEMA3A p.Q511H  3/5  1 
SEMA3A p.G508E  5/5  1 
SEMA3A p.P486L  3/5 Yes 
(Unpublished) 
2 
SEMA3A p.P486Q  3/5  1 
SEMA3A p.R484W  5/5  12 
SEMA3A p.W469C  4/5  1 
SEMA3A p.D454V  4/5  1 
SEMA3A p.F450L  4/5  1 
SEMA3A p.D447G  4/5  4 
SEMA3A p.R438Q  3/5  1 
SEMA3A p.V436I  3/5  2 
SEMA3A p.P407L  4/5  1 
SEMA3A p.I400T  4/5  1 
SEMA3A p.P382A  3/5  1 
SEMA3A p.R359S  4/5  1 
SEMA3A p.R359W  5/5  1 
SEMA3A p.G354S  4/5  1 
SEMA3A p.S331C  4/5  1 
SEMA3A p.H304Q  4/5  1 
SEMA3A p.T303A  4/5  1 
SEMA3A p.R290H  5/5  1 
SEMA3A p.K282R  3/5  1 
SEMA3A p.R264T  5/5  2 
SEMA3A p.R248H  4/5  8 
SEMA3A p.R248C  5/5  2 
SEMA3A p.E214G  4/5  1 
SEMA3A p.G189A  3/5  1 
SEMA3A p.S188C  5/5  1 
SEMA3A 
g.432261G>A 
splice-site —  1 
SEMA3A p.E163V  4/5  1 
SEMA3A p.A106S  3/5  1 
SEMA3A p.R66W LOF33 4/4 Yes33 55 
SEMA3A p.Y36C  4/4  1 
SPRY4 c.896dupT: 
p.F299fs 
frameshift —  1 
SPRY4 p.R274H  5/5  1 
SPRY4 p.R274C  5/5  2 
SPRY4 p.P271S  3/5  1 
SPRY4 p.R267C  3/5  1 
SPRY4 p.R263C  4/5  1 
SPRY4 p.V244E  4/5  1 
SPRY4 p.V244M  3/5  2 
SPRY4 p.R234H  5/5  1 
SPRY4 p.S229F  4/5  2 
SPRY4 p.C226Y  5/5  1 
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SPRY4 p.T198M  5/5  1 
SPRY4 p.C182G  5/5  9 
SPRY4 p.S178F  5/5  1 
SPRY4 p.R174Q  3/5  3 
SPRY4 p.R174W  4/5  3 
SPRY4 p.E160K  3/5  5 
SPRY4 p.G145C  4/4  1 
SPRY4 p.R130H  3/4  1 
SPRY4 p.R130C  3/4  1 
SPRY4 p.P117L  3/4  1 
SPRY4 p.G94R  3/4  2 
SPRY4 p.R80C  4/4  4 
SPRY4 p.R68W  3/4  6 
SPRY4 p.R66W  3/4  7 
SPRY4 p.R30Q  4/4  1 
SPRY4 p.M17T  3/4  1 
SPRY4 c.12delG: 
p.P4fs 
frameshift —  1 
TAC3 g.16064T>C splice-site —  1 
TAC3 p.V87E  5/5  1 
TAC3 p.F85I  4/5  1 
TAC3 p.H83R  5/5  14 
TAC3 p.P77S  3/5  1 
TAC3 p.S65N  4/5  1 
TAC3 p.A9G  3/5  1 
TACR3 p.R425W  3/5  1 
TACR3 p.Y382C  3/5  3 
TACR3 p.C374W  5/5  1 
TACR3 p.R372H  4/5  1 
TACR3 p.R364Q  5/5 Yes25 4 
TACR3 p.R364X nonsense —  1 
TACR3 p.P353S LOF34 5/5 Yes34 1 
TACR3 p.T349P  4/5  1 
TACR3 p.W343X nonsense —  1 
TACR3 p.I320V  3/5  1 
TACR3 p.V298I  3/5  3 
TACR3 p.W275C  5/5  1 
TACR3 p.W275X nonsense — Yes25, 35, 36  25 
TACR3 p.T266I  3/5  1 
TACR3 p.V255M  3/5  1 
TACR3 p.R230H  4/5  3 
TACR3 p.L213P  4/5  3 
TACR3 p.P190A  4/5  4 
TACR3 p.A180E  5/5  1 
TACR3 p.T177M  3/5  1 
TACR3 p.S172T  4/5  1 
TACR3 p.A146V  3/5  1 
TACR3 p.A146T  3/5  1 
TACR3 p.D131N  3/5  1 
TACR3 p.Y122H  4/5  1 
TACR3 p.N121S  4/5  1 
TACR3 p.Y92C  5/5  1 
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TACR3 p.F78L  3/5  1 
TACR3 p.W41X nonsense —  1 
WDR11 p.T5K  3/4  1 
WDR11 p.V6M  4/5  1 
WDR11 p.R13C  4/5  1 
WDR11 p.R85W  4/4  1 
WDR11 p.L132V  4/5  5 
WDR11 p.N145I  4/5  2 
WDR11 p.T150I  4/5  2 
WDR11 p.S165C  3/4  2 
WDR11 p.S186P  3/4  1 
WDR11 p.S208C  3/4  10 
WDR11 p.Q249X nonsense —  1 
WDR11 p.R266P  4/5  1 
WDR11 
c.810delC:p.I270fs 
frameshift —  3 
WDR11 p.L273P  4/5  3 
WDR11 p.R286C  3/4  3 
WDR11 p.Q293X nonsense —  1 
WDR11 g.14447G>A splice-site —  1 
WDR11 
g.14447_14448insC 
splice-site —  1 
WDR11 p.C297R  3/4  1 
WDR11 p.C305Y  4/4  1 
WDR11 p.V380F  3/4  3 
WDR11 p.W383R  4/4  2 
WDR11 p.C516W  3/4  1 
WDR11 p.S531C  4/5  3 
WDR11 p.A533V  4/5  1 
WDR11 p.P591S  3/4  1 
WDR11 p.R598W  4/4  1 
WDR11 p.R640C  3/4  1 
WDR11 p.R703W  4/4  1 
WDR11 p.R703Q  3/4  1 
WDR11 p.L723F  4/5  1 
WDR11 p.S742Y  3/4  1 
WDR11 p.H748R  4/4  1 
WDR11 p.L766S  4/5  1 
WDR11 p.Y770C  3/4  1 
WDR11 p.R792I  3/4  1 
WDR11 p.R797C  4/4  1 
WDR11 p.C804R  3/4  5 
WDR11 p.C804Y  4/4  1 
WDR11 g.39707T>C splice-site —  1 
WDR11 p.L847V  4/5  1 
WDR11 p.R918W  4/4  1 
WDR11 p.Y920C  3/4  4 
WDR11 p.S924L  4/4  2 
WDR11 p.Y935C  3/4  1 
WDR11 p.C966R  4/4  2 
WDR11 c.3006delC: 
p.D1002fs 
frameshift —  1 
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WDR11 p.G1008D  3/4  6 
WDR11 p.S1042L  4/4  1 
WDR11 p.Q1047X nonsense —  1 
WDR11 g.54135A>G splice-site —  1 
WDR11 g.54136G>A splice-site —  2 
WDR11 p.D1078N  4/5  1 
WDR11 p.T1085I  4/4  1 
WDR11 p.R1091W  4/4  2 
WDR11 p.W1094R  3/4  1 
WDR11 p.D1107N  4/5  2 
WDR11 p.R1111W  4/4  1 
WDR11 p.L1116F  4/5  1 
WDR11 p.S1133P  4/4  1 
WDR11 p.G1135D  4/4  2 
WDR11 p.L1144H  4/5  1 
WDR11 p.A1154T  4/5  1 
WDR11 p.F1156S  3/4  1 
WDR11 p.K1162T  3/4  1 
WDR11 p.G1191S  4/5  13 
WDR11 p.G1204R  3/4   2 
WDR11 p.L1211S  4/5  4 
Abbreviation: ExAC, Exome Aggregation Consortium; LOF, loss-of-function as indicated 
by significantly decreased performance in in vitro functional assays compared to wild-type; 
Ref., reference; —, not tested 
*Not all prediction programs gave predictions for all variants. 
  †Each allele with a potentially pathogenic variant was counted as one individual subject for 
statistical analysis. 
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